KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Amortization of Deferred Charges: 2009-2024

Historic Amortization of Deferred Charges for Biomarin Pharmaceutical (BMRN) over the last 15 years, with Dec 2024 value amounting to $3.4 million.

  • Biomarin Pharmaceutical's Amortization of Deferred Charges fell 9.61% to $649,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 million, marking a year-over-year decrease of 28.73%. This contributed to the annual value of $3.4 million for FY2024, which is 19.79% down from last year.
  • According to the latest figures from FY2024, Biomarin Pharmaceutical's Amortization of Deferred Charges is $3.4 million, which was down 19.79% from $4.2 million recorded in FY2023.
  • Over the past 5 years, Biomarin Pharmaceutical's Amortization of Deferred Charges peaked at $16.5 million during FY2020, and registered a low of $3.4 million during FY2024.
  • Over the past 3 years, Biomarin Pharmaceutical's median Amortization of Deferred Charges value was $4.1 million (recorded in 2022), while the average stood at $3.9 million.
  • In the last 5 years, Biomarin Pharmaceutical's Amortization of Deferred Charges grew by 18.27% in 2020 and then slumped by 74.89% in 2021.
  • Biomarin Pharmaceutical's Amortization of Deferred Charges (Yearly) stood at $16.5 million in 2020, then tumbled by 74.89% to $4.1 million in 2021, then declined by 0.70% to $4.1 million in 2022, then climbed by 1.72% to $4.2 million in 2023, then declined by 19.79% to $3.4 million in 2024.